700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 543
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer | S.O. | S.O. | 1968 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
L’ISS Governance QualityScore de Novavax, Inc. en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 7; Société : 4; Droits des actionnaires : 5; Compensation : 5.